Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Boehringer Ingelheim
Chubb
Moodys
Deloitte

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 6,740,655

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,740,655
Title: Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
Abstract:This invention is directed to compounds of the formula: ##STR1## wherein j is 0 or 1; k is 0 or 1; m is 0 or 1; n is 0 or 1; W is --O--; --S(.dbd.O).sub.t --, where t is 0, 1, or 2; or --N(R.sup.3)--; where R.sup.3 is --H, --(C.sub.1 -C.sub.3) alkyl, --OR.sup.12, phenyl, or benzyl; R.sup.C and R.sup.D have the same meaning as R.sup.A and R.sup.B, except that at least one of R.sup.C and R.sup.D must be --H; and the other variables are defined as set forth in the specification. The invention is also directed to pharmaceutical compositions comprising the above compounds and to methods of treating a subject suffering from a disease, disorder or condition mediated by the PDE4 isozyme, the method comprising administering a therapeutically effective amount of a compound as described above. The invention is particularly directed to methods of treating inflammatory, respiratory and allergic diseases and conditions, especially asthma; chronic obstructive pulmonary disease (COPD) including chronic bronchitis, emphysema, and bronchiectasis; chronic rhinitis; and chronic sinusitis.
Inventor(s): Magee; Thomas Victor (Mystic, CT), Marfat; Anthony (Mystic, CT), Chambers; Robert James (Mystic, CT)
Assignee: Pfizer Inc (New York, NY)
Application Number:10/181,417
Patent Claims:see list of patent claims

Details for Patent 6,740,655

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Pfizer Inc (New York, NY) 2017-04-04 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Pfizer Inc (New York, NY) 2017-04-04 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up Pfizer Inc (New York, NY) 2017-04-04 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up Pfizer Inc (New York, NY) 2017-04-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Medtronic
Merck
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.